We’ll be conducting routine maintenance from Saturday, July 27th through Sunday, July 28th.
Our phone system will be unavailable during this time, but you’ll be able to chat with our live agents 24/7 or you can email Support.

Noom Med

A revolutionary approach to GLP-1s and obesity care.

Noom Med, our powerful obesity care solution—now with SmartRx—combines biology and psychology to deliver better outcomes and lower overall costs. With a proven 4.1x ROI and SmartRx further enhancing ROI, Noom Med drives long-term success for both individuals and organizations.
Noom Weight

Affordable GLP-1 access with a breakthrough pharmacy solution.

While GLP-1s have revolutionized healthcare, they come at a cost. Noom’s SmartRx pharmacy carve-out solution, an enhancement of Noom Med, provides transparent, discounted pricing on GLP-1 medications for weight loss, with the flexibility to set custom copays separate from other covered medications.

60%

Bypass PBM intermediaries for cost-effective, uninterrupted medication access

30%

Access branded GLP-1 medications at reduced prices and decide how to share costs with employees

Ensure rapid access to GLP-1 medications within 5 days to drive increased persistence anD better health outcomes

Higher ROI. Better outcomes. Healthier people.

Based in cognitive science, Noom Med delivers maintainable outcomes through evidence-based obesity care that combines sustainable lifestyle changes with medication-assisted weight loss as needed, ultimately maximizing ROI.

Evidence-based protocols

Proven experience showing that while GLP-1 medications are an effective tool for weight management, their efficacy is significantly enhanced when paired with robust lifestyle interventions.

Reducing the yo-yo effect

A structured approach to medication tapering that begins with medication support, and balances medical needs and costs to avoid weight regain as part of the “yo-yo” cycle.

World class behavior change

We utilize our award-winning behavior change program as the foundation of our care model to enhance health outcomes and ensure lasting ROI.

Positive ROI accumulation

A proven track record of delivered, measurable health improvements and cost savings, providing partners with a 4.1X ROI over a three-year period.

Combining mind and medicine, for lasting health outcomes.

CLINICAL & MEDICATION Care
Obesity care clinicians provide personalized support from initial assessment to continuous care, including prescribing medications based on individual needs of each patient.
INTENSIVE BEHAVIOR CHANGE
Members have access to health coaching, a supportive community, and a psychology-driven digital curriculum designed to foster lasting behavior change.
CARE TOOLS AND RESOURCES
Patients are provided with the tools and resources necessary to allow clinicians to track progress and make timely, personalized adjustments to their treatment plan.
GLP-1 COMPANION
Embedded care pathway that provides tailored support to members taking a GLP-1 or other anti-obesity medication.

Obesity care clinicians provide personalized support from initial assessment to continuous care, including prescribing medications based on individual needs of each patient.

Members have access to health coaching, a supportive community, and a psychology-driven digital curriculum designed to foster lasting behavior change.

Patients are provided with the tools and resources necessary to allow clinicians to track progress and make timely, personalized adjustments to their treatment plan.

Embedded care pathway that provides tailored support to members taking a GLP-1 or other anti-obesity medication.

Real support leads to real results.

Proven outcomes in 50+ peer-reviewed publications and 10+ academic medical research collaborations.
0%
are expected to start with an
alternative to GLP-1s1
0X
more weight loss reported when
pairing Noom with an early GLP-1
vs a GLP-1 alone2
0X
projected ROI in
healthcare and cost
savings over 3 years3

The proof is in the members.

The all-in-one solution to healthy living and lower costs.

Bring Noom to your organization today.

By submitting this form, you consent to our Terms and Conditions.

  1. Third-party validated actuarial analysis, October 2024. This projection is based on a comparison to a status quo scenario where GLP-1 medication spending is uncontrolled. ROI may vary based on factors such as company size, employee health profiles, and current healthcare costs.
  2. Based on a retrospective study of self-reported data of pounds lost for active versus passive users who were offered the Noom program when being prescribed an early stage GLP-1.
  3. Third-party validated actuarial analysis, October 2024. This projection is based on a comparison to a status quo scenario where GLP-1 medication spending is uncontrolled. ROI may vary based on factors such as company size, employee health profiles, and current healthcare costs.
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.